TD Cowen Lifts PT on Royalty Pharma Plc (RPRX) to $50 from $45, Here's Why

Royalty Pharma Plc (NASDAQ:RPRX) is one of the best cheap biotech stocks to buy now. TD Cowen lifted the price target on Royalty Pharma Plc (NASDAQ:RPRX) to $50 from $45 on February 27, maintaining a Buy rating on the shares and telling investors that the company is poised to benefit from unique strengths, including differentiation from its competitors, growth of the biopharma royalty market, and the diversification of its portfolio. The firm thus updated its model to take into account these and other tailwinds.

Royalty Pharma Plc (NASDAQ:RPRX) also received a rating update from Goldman Sachs on February 12. The firm lifted the price target on the stock to $51 from $45 and reiterated a Buy rating on the shares. It told investors in a research note that Royalty Pharma Plc (NASDAQ:RPRX) reported solid fiscal Q4 results, with portfolio receipts and 2026 guidance surpassing expectations, implying 3%-8% year over year growth in royalty receipts. According to Goldman Sachs, Royalty Pharma Plc (NASDAQ:RPRX) remains on track for long-term 10%+ top-line growth, supported by a healthy royalty financing market, robust synthetic royalty performance, and continued commercial momentum, with its $3.5 billion financial capacity also supporting active capital deployment.

Royalty Pharma Plc (NASDAQ:RPRX) funds innovation in the biopharmaceutical industry and buys biopharmaceutical royalties. It collaborates with innovators from research hospitals, non-profits, and academic institutions through small and mid-cap biotech companies to global pharma companies. The company funds innovation in the industry both directly, by partnering with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly, by acquiring existing royalties from the original innovators.